Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
10:32am, Monday, 18'th Sep 2023
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.
Incyte shares drop after FDA approves GSK's competing blood-cancer treatment
08:11am, Monday, 18'th Sep 2023
Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil
US FDA approves GSK's anemia treatment
04:25pm, Friday, 15'th Sep 2023
British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.
EU regulator recommends to stop sale of GSK's blood cancer drug
08:56am, Friday, 15'th Sep 2023
The European Medicines Agency's human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK's blood cancer drug Blenrep.
GSK opens new site in UK unlike rival AstraZeneca
08:22am, Thursday, 14'th Sep 2023
GSK has opened a new £65 million drug factory in Hertfordshire in a move it said would enable rapid production of medicines developed through its research pipeline. In contrast to UK rival AstraZenec
GSK (GSK) Moves 5.5% Higher: Will This Strength Last?
05:16am, Monday, 11'th Sep 2023
GSK (GSK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
International Wide-Moat Stocks On Sale - The September 2023 Heat Map
09:05pm, Thursday, 07'th Sep 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of th
GSK plc (GSK) Citi's 18th Annual BioPharma Conference Transcript
12:59pm, Thursday, 07'th Sep 2023
GSK plc (NYSE:GSK ) Citi's 18th Annual BioPharma Conference September 7, 2023 8:50 AM ET Company Participants Phil Dormitzer - SVP, Head of Vaccines R&D Conference Call Participants Andrew Baum - Citi
Ineos, Esso and GSK face potential strikes as contractors balloted over pay dispute
10:06am, Thursday, 07'th Sep 2023
Several UK oil refineries owned by Ineos, along with power stations, chemical and sites, including for Esso, Essar and GSK PLC (LSE:GSK, NYSE:GSK) are facing disruption from potential strikes over
7 Stocks Hedge Funds Are Loading Up On
05:22pm, Sunday, 03'rd Sep 2023
Emulating the moves of hedge fund stock pickers, and some of the most successful hedge funds can produce sizable profits for retail investors. In fact, here are seven of the top institutional stock pi
GSK's new drug application for Nucala accepted for review in Japan
02:29am, Friday, 01'st Sep 2023
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japanese authorities have accepted for review a supplementary new drug application (sNDA) for Nucala, a treatment for chronic rhinosinusitis with nas
3 Growth Stocks to Ride the Coming Bull Market in Style
12:01pm, Saturday, 26'th Aug 2023
Stocks are rallying once again in 2023. The growth-oriented index is leading the way higher with a 36% gain or more than twice the return of the S&P 500.
Here's Why GSK (GSK) is a Strong Value Stock
11:16am, Friday, 25'th Aug 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK's Shingrix proves 100% effective against shingles in China trial
03:04am, Wednesday, 23'rd Aug 2023
GSK PLC (LSE:GSK, NYSE:GSK) announced that its Shingrix vaccine demonstrated 100% efficacy in preventing shingles among adults aged 50 and over in China. The data comes from the first efficacy trial
3 Sorry Pharma Stocks to Sell in August Before It's Too Late
04:38pm, Tuesday, 22'nd Aug 2023
Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery.
